![]() | |
Legal status | |
---|---|
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChemCID | |
ChemSpider |
|
UNII | |
ChEMBL | |
CompTox Dashboard(EPA) | |
Chemical and physical data | |
Formula | C22H25NO2 |
Molar mass | 335.447 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
JWH-250 or (1-pentyl-3-(2-methoxyphenylacetyl)indole) is ananalgesic chemical from thephenylacetylindole family that acts as acannabinoidagonist at both theCB1 andCB2 receptors, with aKi of 11 nM at CB1 and 33 nM at CB2. Unlike many of the olderJWH series compounds, this compound does not have anaphthalene ring, instead occupying this position with a 2'-methoxy-phenylacetyl group, making JWH-250 a representative member of a new class of cannabinoid ligands.[4] Other 2'-substituted analogues such as themethyl,chloro andbromo compounds are also active and somewhat more potent.[5][6]
JWH-250 was discovered by, and named after the researcherJohn W. Huffman. He created JWH-250 and a number of other compounds to research the structure and function of theendocannabinoid system ofmammals. Samples of JWH-250 were first identified in May 2009 by the German Federal Criminal Police, as an ingredient in new generation "herbal smoking blends" that had been released since the banning of the original ingredients(C8)-CP 47,497 andJWH-018.[7] An ELISA immunoassay technique for detecting JWH-250 in urine has been reported.[8]
JWH-250 is considered a Schedule 9 prohibited substance in Australia under thePoisons Standard (October 2015).[9] A Schedule 9 substance is a substance which may be abused or misused, the manufacture, possession, sale or use of which should be prohibited by law except when required for medical or scientific research, or for analytical, teaching or training purposes with approval of Commonwealth and/or State or Territory Health Authorities.[9]
In the United States, CB1 receptor agonists of the 3-phenylacetylindole class such as JWH-250 areSchedule I Controlled Substances.[10]